Transthyretin-Synthesis
TTR is a 55kDa plasma homotetrameric protein that was first discovered in 1942. In the CSF, it is the main iodothyronine-binding protein, transferring T 4 from the blood into the brain across the blood-choroid plexus barrier. [5] [6] [7] Serum TTR is also involved in the transport of plasma retinol-binding protein complex to vitamin A. 8 TTR is synthesized in the liver and the choroid plexus of the brain, 9, 10 and TTR messenger RNA (mRNA) has also been found in kidney cells. 11 In the CSF it is composed of two fractions: one originating in the blood (about 10%) and one from the choroid plexus. 12 Studies on the plexus fraction are limited, but they are extremely important and urgently needed, since both morphological and functional changes in the choroid plexus are known to occur in AD. The ratio of the concentration of TTR in CSF to the concentration in serum is 200 times in excess compared with albumin. 13 The concentration of TTR in serum is a sensitive indicator for malnutrition and illness owing to a reduction in its production rate in combination with its very rapid rate of disappearance from the circulation: about 50% per day. 
Pathology/Effect on Aβ Aggregation
Aggregates of the amyloidogenic (Aβ 1-42 ) peptide play a major role in the pathogenesis of AD, although the precise mechanism is unclear. 18 TTR levels in the CSF of patients with AD are shown to be reduced in comparison with patients without dementia. 13, 22, 27 Other studies have reported decreased TTR concentrations in the CSF of patients with depression and normal pressure hydrocephalus (NPH). 28, 30 Although hampered by an artificial study design, similar results were achieved for post mortem CSF in AD. 31 In other neurodegenerative diseases, normal concentrations of TTR are detected. 30 33 found no associations between tau and p-tau with dementia severity in AD. In another study that analyzed tau, Aβ , and TTR in the same population, clear differences between biomarkers were elucidated. Whereas no association of dementia severity with tau and Aβ 1-42 levels were detected, this was clearly observed for TTR: patients with severe AD showed a significantly lower TTR concentration (p=0.05) compared with mild cognitive impairment or mild dementia. At a cut-off of 15mg/l both stages could be discriminated, with a sensitivity of 91% and a specificity of 75% (Youden=0.66). Such an effect was not seen in patients with NPH (see Figure 2) . 30 In summary, TTR levels have been demonstrated to be selectively decreased in AD compared with other dementia. In addition, some data indicate that levels reflect disease severity in AD, which makes this protein an interesting biomarker for AD diagnosis.
Studies on early AD stages are lacking so far, and more must follow. n
